Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹1609 Cr.
Stock P/E
112.3
P/B
2.5
Current Price
₹302.4
Book Value
₹ 119
Face Value
2
52W High
₹374.4
52W Low
₹ 164.2
Dividend Yield
0%

Tarsons Products Overview

Business

Tarsons Products Ltd. is a leading Indian manufacturer and supplier of high-quality laboratory plasticware, equipment, and other consumables. The company primarily caters to customers in the life sciences, healthcare, research, and industrial sectors. Its core business model involves designing, manufacturing, and distributing a wide range of plastic products essential for laboratory applications, including consumables (e.g., petri dishes, pipette tips), reusables (e.g., bottles, beakers), and select instruments. Tarsons generates revenue by selling these products to research institutions, pharmaceutical companies, diagnostic labs, academic institutions, and various industries both in India and internationally.

Revenue Mix

Tarsons Products Ltd. primarily operates in a single overarching segment: Laboratory Plasticware and related products. Within this segment, their product portfolio can be broadly categorized into:

Lab Consumables: Disposable items like centrifuge tubes, petri dishes, pipette tips, cryogenic vials, filter tips, etc., which account for a significant portion of their sales.

Lab Reusables: Durable plasticware such as bottles, carboys, beakers, measuring cylinders, funnels, and other general labware.

Lab Instruments: Smaller, specialized equipment and accessories used in laboratory settings.

As a company focused on this niche, segment-wise revenue splits are not typically reported as distinct business units.

Industry

Tarsons operates in the laboratory plasticware industry, which is a sub-segment of the broader scientific and laboratory equipment market. This industry in India is characterized by growth driven by increasing R&D activities, expansion in healthcare infrastructure, and a robust pharmaceutical and biotechnology sector. The market includes both domestic manufacturers and international players. Tarsons is positioned as one of the leading Indian manufacturers, known for its comprehensive product range and adherence to international quality standards (e.g., ISO, CE). It competes with both smaller unorganized domestic players and larger global brands that have a presence in India.

MOAT

Extensive Product Portfolio: A wide and deep range of over 1,700 products caters to diverse laboratory needs, making it a one-stop shop for many customers.

Manufacturing Scale & Quality: Significant manufacturing capacity with adherence to international quality and regulatory standards (e.g., ISO 9001:2015, ISO 13485:2016, CE IVD certified products), which is critical for lab products.

Distribution Network: A well-established pan-India distribution network and growing international presence ensure widespread product availability.

Brand Recognition: An established and trusted brand name within the Indian scientific community and among procurement managers in research and healthcare.

Operational Efficiency: Integrated manufacturing facilities allow for cost control and customization.

Growth Drivers

Growing Life Sciences & Healthcare Sector: Increased R&D spending by pharmaceutical, biotechnology, and academic institutions, along with expansion of diagnostics and healthcare facilities.

Government Initiatives: "Make in India" initiatives and increased government funding for scientific research and healthcare infrastructure.

Rising Diagnostics Demand: Growing awareness and need for advanced diagnostic testing contribute to demand for lab consumables.

Export Market Expansion: Increasing penetration into international markets, leveraging competitive pricing and quality.

New Product Development: Continuous introduction of innovative and specialized lab plasticware to meet evolving scientific requirements.

Risks

Raw Material Price Volatility: Dependence on crude oil derivatives (polymers) makes the company susceptible to fluctuations in petrochemical prices.

Intense Competition: Competition from both established international players and numerous smaller domestic manufacturers can lead to pricing pressure.

Economic Slowdown: A downturn in the economy could lead to reduced R&D budgets or slower healthcare sector growth, impacting demand.

Technological Obsolescence: Failure to innovate or adapt to new laboratory technologies and product requirements could impact market relevance.

Regulatory Changes: Evolving health and safety standards or import/export regulations for laboratory products could impact operations.

Foreign Exchange Fluctuations: Impact on import costs for machinery/specialized raw materials and export revenues.

Management & Ownership

Tarsons Products Ltd. is promoted by the Sehgal family, with Mr. Sanjive Sehgal serving as the Chairman & Managing Director and Mr. Rohan Sehgal as the Joint Managing Director. The promoters hold a significant stake in the company, a common characteristic of many Indian businesses, indicating alignment of interests. The management team has extensive experience in the laboratory products industry, driving the company's growth and operational strategy.

Outlook

Tarsons Products is well-positioned to capitalize on the secular growth trends in the Indian life sciences, healthcare, and research sectors. The "Make in India" impetus, coupled with increasing R&D expenditure and expansion of diagnostic capabilities, provides a favorable domestic environment. The company's established brand, comprehensive product portfolio, and expanding distribution network give it a strong foundation for continued growth, potentially bolstered by increasing export opportunities. However, the business faces inherent risks from raw material price volatility, intense competition, and the constant need for product innovation. Maintaining cost efficiency while continuing to expand its product offerings and market reach, both domestically and internationally, will be crucial for sustained performance amidst a competitive landscape.

Tarsons Products Share Price

Live · BSE / NSE · Inception: 1983
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Tarsons Products Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 106 85 99 96 113 91 102 108 121 110
Other Income 3 3 8 1 4 3 6 8 7 6
Total Income 109 88 108 97 116 95 108 116 128 116
Total Expenditure 75 66 74 66 76 67 75 76 87 84
Operating Profit 34 22 34 30 41 28 33 40 41 32
Interest 4 4 5 5 5 5 5 6 6 6
Depreciation 12 11 14 17 20 20 22 25 29 27
Exceptional Income / Expenses 0 0 0 0 0 0 0 -1 0 0
Profit Before Tax 17 6 15 8 16 3 6 8 6 -1
Provision for Tax 7 2 5 3 5 1 2 2 2 0
Profit After Tax 10 4 10 5 10 2 3 5 4 -1
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 10 4 10 5 10 2 3 5 4 -1
Adjusted Earnings Per Share 1.9 0.8 1.9 1 1.9 0.3 0.6 0.9 0.8 -0.3

Tarsons Products Profit & Loss

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 229 301 296 392 423 441
Other Income 6 8 11 16 25 27
Total Income 234 309 308 408 447 468
Total Expenditure 126 148 197 282 305 322
Operating Profit 109 161 111 127 142 146
Interest 3 4 10 20 23 23
Depreciation 14 22 40 62 97 103
Exceptional Income / Expenses 0 0 0 0 -1 -1
Profit Before Tax 92 135 61 45 22 19
Provision for Tax 24 34 18 15 8 6
Profit After Tax 69 101 43 30 14 11
Adjustments 0 0 0 0 0 0
Profit After Adjustments 69 101 43 30 14 11
Adjusted Earnings Per Share 13.5 18.9 8 5.6 2.7 2

Tarsons Products Balance Sheet

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 244 490 613 630 635
Minority's Interest 0 0 0 0 0
Borrowings 3 9 102 205 210
Other Non-Current Liabilities 102 139 44 69 77
Total Current Liabilities 42 35 229 190 264
Total Liabilities 392 673 988 1094 1186
Fixed Assets 120 189 336 536 733
Other Non-Current Assets 159 240 401 301 187
Total Current Assets 113 245 252 257 266
Total Assets 392 673 988 1094 1186

Tarsons Products Cash Flow

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 25 2 64 17 25
Cash Flow from Operating Activities 68 83 103 114 118
Cash Flow from Investing Activities -64 -138 -285 -145 -130
Cash Flow from Financing Activities -27 130 136 39 9
Net Cash Inflow / Outflow -23 75 -47 8 -3
Closing Cash & Cash Equivalent 2 77 17 25 23

Tarsons Products Ratios

# Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 13.54 18.92 8.01 5.6 2.69
CEPS(Rs) 16.22 23.05 15.61 17.34 20.83
DPS(Rs) 0 0 2 0 0
Book NAV/Share(Rs) 48.02 92.06 115.19 118.45 119.29
Core EBITDA Margin(%) 45.11 50.77 33.69 28.26 27.84
EBIT Margin(%) 41.57 46.28 23.93 16.4 10.57
Pre Tax Margin(%) 40.38 44.88 20.5 11.42 5.18
PAT Margin (%) 30.09 33.47 14.39 7.59 3.39
Cash Profit Margin (%) 36.05 40.77 28.02 23.51 26.24
ROA(%) 17.58 18.9 5.13 2.86 1.26
ROE(%) 28.19 27.42 7.73 4.79 2.26
ROCE(%) 34.25 35.28 10.27 7.04 4.52
Receivable days 75 68.08 88.09 73.25 71.27
Inventory Days 74.46 78.31 129.98 118.49 110.5
Payable days 35.46 54.91 61.26 42.79 47.34
PER(x) 0 37.22 49.17 53.92 61.95
Price/Book(x) 0 7.65 3.42 2.55 1.4
Dividend Yield(%) 0 0 0.51 0 0
EV/Net Sales(x) 0.13 12.24 7.86 4.86 2.95
EV/Core EBITDA(x) 0.28 22.85 20.94 15.04 8.75
Net Sales Growth(%) 0 31.4 -1.46 32.4 7.67
EBIT Growth(%) 0 46.29 -49.06 -9.27 -30.61
PAT Growth(%) 0 46.17 -57.64 -30.18 -51.89
EPS Growth(%) 0 39.78 -57.64 -30.18 -51.89
Debt/Equity(x) 0.14 0.04 0.42 0.52 0.6
Current Ratio(x) 2.7 7 1.1 1.35 1.01
Quick Ratio(x) 1.58 4.64 0.54 0.69 0.51
Interest Cover(x) 34.96 33.02 6.99 3.29 1.96
Total Debt/Mcap(x) 0 0.01 0.12 0.2 0.43

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +8% +12% — —
Operating Profit CAGR +12% -4% — —
PAT CAGR -53% -48% — —
Share Price CAGR +4% -14% — —
ROE Average +2% +5% +14% +14%
ROCE Average +5% +7% +18% +18%

Tarsons Products Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 47.3 %
FII 0.55 %
DII (MF + Insurance) 0.61 %
Public (retail) 51.53 %
Others 0.01 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 47.3147.3147.3147.3147.3147.3147.347.347.347.3
FII 7.958.047.519.529.145.822.470.870.160.55
DII 0.110.210.250.040.040.0800.190.10.61
Public 44.6344.4544.9443.1343.5246.7850.2351.6452.4451.53
Others 0000000000
Total 100100100100100100100100100100

Tarsons Products Peer Comparison

Plastic Products Edit Columns

Tarsons Products Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Tarsons Products Pros & Cons

Pros

Cons

  • Promoter holding is low: 47.3%.
  • Company has a low return on equity of 5% over the last 3 years.
  • Debtor days have increased from 42.79 to 47.34days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp